Advances in the validation of lung ultrasound for the detection of interstitial lung disease associated with rheumatoid arthritis

Abstract

Interstitial lung disease (ILD) is one of the most important extra-articular manifestations of rheumatoid arthritis (RA) due to its associated significant mortality. The availability of pharmacological treatments capable of slowing its progression, especially when initiated early, makes early diagnosis an essential part of its management. The low sensitivity of chest X-ray or lung function tests to identify RA-ILD in the early stages of the disease, together with the cost, accessibility, and ionizing radiation limitations of high-resolution computed tomography (HRCT), especially when serial screening or follow-up studies are required, has prompted the study of lung ultrasound (LUS) as an additional aid for the screening, diagnosis, and/or follow-up of RA-ILD. Based on the safety, low cost, and accessibility of LUS, and the encouraging results of research into this technique in ILD associated with systemic sclerosis, progress has been made in its validation process with research addressing aspects such as its accuracy, feasibility, and reliability. Negative predictive value and sensitivity values exceeding 80–90% have been reported, suggesting its potential utility. Feasibility has been suggested since LUS scan can be performed in less than 10 minutes, and intra- and inter-observer or examiner reliability shows values in the good to excellent range. However, there are still aspects that require further investigation, such as the standardization of the LUS scanning protocol or the requirements to ensure an effective learning curve before applying the technique in clinical practice. It is necessary to recognize the inherent limitations of LUS and understand that it should be considered a tool to aid in the early identification of patients who require HRCT, which is currently the diagnostic gold standard.

Keywords

rheumatoid arthritis / interstitial lung disease / lung ultrasound / accuracy / reliability

References

[1] Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016; 388: 2023-38.

[2] Spagnolo P, Lee JS, Sverzellati N, Rossi G, Cottin V. The Lung in Rheumatoid Arthritis: Focus on Interstitial Lung Disease. Arthritis Rheumatol. 2018; 70: 1544-54.

[3] Hyldgaard C, Hilberg O, Pedersen AB, Ulrichsen SP, Løkke A, Bendstrup E, et al. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis. 2017; 76: 1700-6.

[4] Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010; 62: 1583-91.

[5] Solomon JJ, Chung JH, Cosgrove GP, Demoruelle MK, Fernandez-Perez ER, Fischer A, et al. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2016; 47: 588-96.

[6] Zamora-Legoff JA, Krause ML, Crowson CS, Ryu JH, Matteson EL. Progressive Decline of Lung Function in Rheumatoid Arthritis-Associated Interstitial Lung Disease. Arthritis Rheumatol. 2017; 69: 542-9.

[7] Olson A, Hartmann N, Patnaik P, Wallace L, Schlenker-Herceg R, Nasser M, et al. Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey. Adv Ther. 2021; 38: 854-67.

[8] Hyldgaard C, Ellingsen T, Hilberg O, Bendstrup E. Rheumatoid Arthritis-Associated Interstitial Lung Disease: Clinical Characteristics and Predictors of Mortality. Respiration. 2019; 98: 455-60.

[9] Vicente-Rabaneda EF, Atienza-Mateo B, Blanco R, Cavagna L, Ancochea J, Castañeda S, et al. Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review. Autoimmun Rev. 2021; 20: 102830.

[10] Serrano-Combarro A, Atienza-Mateo B, Martín-Gutiérrez A, Loarce-Martos J, Dubuc CAE, Pastor Mena M, et al.; Spanish Collaborative Group of JAKi in Interstitial Lung Disease Associated with Rheumatoid Arthritis. Baricitinib in rheumatoid arthritis-interstitial lung disease: a literature review and national multicentre study of 72 patients. Rheumatology (Oxford). 2025; 64: 5471-80.

[11] Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al.; INBUILD Trial Investigators. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019; 381: 1718-27.

[12] McDermott GC, Doyle TJ, Sparks JA. Interstitial lung disease throughout the rheumatoid arthritis disease course. Curr Opin Rheumatol. 2021; 33: 284-91.

[13] Garrote-Corral S, Silva-Fernández L, Seoane-Mato D, Guerra-Rodríguez M, Aburto M, Castañeda S, et al. Screening of interstitial lung disease in patients with rheumatoid arthritis: A systematic review. Reumatol Clin (Engl Ed). 2022; 18: 587-96.

[14] Juge PA, Crestani B, Dieudé P. Recent advances in rheumatoid arthritis-associated interstitial lung disease. Curr Opin Pulm Med. 2020; 26: 477-86.

[15] Paulin F, Doyle TJ, Mercado JF, Fassola L, Fernández M, Caro F, et al. Development of a risk indicator score for the identification of interstitial lung disease in patients with rheumatoid arthritis. Reumatol Clin (Engl Ed). 2021; 17: 207-11.

[16] Koduri GM, Podlasek A, Pattapola S, Zhang J, Laila D, Nandagudi A, et al. Four-factor risk score for the prediction of interstitial lung disease in rheumatoid arthritis. Rheumatol Int. 2023; 43: 1515-23.

[17] Xue J, Hu W, Wu S, Wang J, Chi S, Liu X. Development of a Risk Nomogram Model for Identifying Interstitial Lung Disease in Patients With Rheumatoid Arthritis. Front Immunol. 2022; 13: 823669.

[18] Juge PA, Granger B, Debray MP, Ebstein E, Louis-Sidney F, Kedra J, et al. A Risk Score to Detect Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease. Arthritis Rheumatol. 2022; 74: 1755-65.

[19] Wheeler AM, Baker JF, Riley T, Yang Y, Roul P, Wysham KD, et al. Development and internal validation of a clinical and genetic risk score for rheumatoid arthritis-associated interstitial lung disease. Rheumatology (Oxford). 2025; 64: 268-75.

[20] Narváez J, Aburto M, Seoane-Mato D, Bonilla G, Acosta O, Candelas G, et al. Screening criteria for interstitial lung disease associated to rheumatoid arthritis: Expert proposal based on Delphi methodology. Reumatol Clin (Engl Ed). 2023; 19: 74-81.

[21] Johnson SR, Bernstein EJ, Bolster MB, Chung JH, Danoff SK, George MD, et al. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Rheumatol. 2024; 76: 1201-13.

[22] Vicente-Rabaneda EF, Acebes C, Castañeda S. Usefulness of extra-articular ultrasound applied to systemic inflammatory diseases in clinical practice. Reumatol Clin (Engl Ed). 2021; 17: 229-36.

[23] Delle Sedie A, Terslev L, Bruyn GAW, Cazenave T, Chrysidis S, Diaz M, et al. Standardization of interstitial lung disease assessment by ultrasound: results from a Delphi process and web-reliability exercise by the OMERACT ultrasound working group. Semin Arthritis Rheum. 2024; 65: 152406.

[24] Vicente-Rabaneda EF, Bong DA, Castañeda S, Möller I. Use of ultrasound to diagnose and monitor interstitial lung disease in rheumatic diseases. Clin Rheumatol. 2021; 40: 3547-64.

[25] Vicente-Rabaneda EF, Bong DA, Busquets-Pérez N, Möller I. Ultrasound Evaluation of Interstitial Lung Disease in Rheumatoid Arthritis and Autoimmune Diseases. Eur J Rheumatol. 2024; 11: S316-22.

[26] Moazedi-Fuerst FC, Kielhauser SM, Scheidl S, Tripolt NJ, Lutfi A, Yazdani-Biuki B, et al. Ultrasound screening for interstitial lung disease in rheumatoid arthritis. Clin Exp Rheumatol. 2014; 32: 199-203.

[27] Fotoh DS, Helal A, Rizk MS, Esaily HA. Serum Krebs von den Lungen-6 and lung ultrasound B lines as potential diagnostic and prognostic factors for rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol. 2021; 40: 2689-97.

[28] Mena-Vázquez N, Jimenez-Núñez FG, Godoy-Navarrete FJ, Manrique-Arija S, Aguilar-Hurtado MC, Romero-Barco CM, et al. Utility of pulmonary ultrasound to identify interstitial lung disease in patients with rheumatoid arthritis. Clin Rheumatol. 2021; 40: 2377-85.

[29] Gutierrez M, Ruta S, Clavijo-Cornejo D, Fuentes-Moreno G, Reyes-Long S, Bertolazzi C. The emerging role of ultrasound in detecting interstitial lung disease in patients with rheumatoid arthritis. Joint Bone Spine. 2022; 89: 105407.

[30] Tüzün Z, Aydın K, Türk İ, Varkal G, Kırmızıer G, Doğru H, et al. Evaluation of the coalescent lung ultrasound score in rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol. 2025; 44: 3459-65.

[31] Cogliati C, Antivalle M, Torzillo D, Birocchi S, Norsa A, Bianco R, et al. Standard and pocket-size lung ultrasound devices can detect interstitial lung disease in rheumatoid arthritis patients. Rheumatology (Oxford). 2014; 53: 1497-503.

[32] Di Carlo M, Tardella M, Filippucci E, Carotti M, Salaffi F. Lung ultrasound in patients with rheumatoid arthritis: definition of significant interstitial lung disease. Clin Exp Rheumatol. 2022; 40: 495-500.

[33] Otaola M, Paulin F, Rosemffet M, Balcazar J, Perandones M, Orausclio P, et al. Lung ultrasound is a promising screening tool to rule out interstitial lung disease in patients with rheumatoid arthritis. Respirology. 2024; 29: 588-95.

[34] Santos-Moreno P, Linares-Contreras MF, Rodríguez-Vargas GS, Rodríguez-Linares P, Mata-Hurtado A, Ibatá L, et al. Usefulness of Lung Ultrasound as a Method for Early Diagnosis of Interstitial Lung Disease in Patients with Rheumatoid Arthritis. Open Access Rheumatol. 2024; 16: 9-20.

[35] Tanten Zabaleta R, Marín J, Zacariaz Hereter JB, Maritano J, Fullana M, Alvarado N, et al. Clinical utility of lung ultrasound for the detection of interstitial lung disease in patients with rheumatoid arthritis. Reumatismo. 2024; 76: 278-85.

[36] Reichenberger F, Popp F, Hoffmann M, Fischinger C, von Wulffen W, Kneidinger N, et al. Proposal of a radiation-free screening protocol for early detection of interstitial lung involvement in seropositive and ACPA-positive rheumatoid arthritis. BMC Pulm Med. 2024; 24: 581.

[37] Schneeberger EE, Perandones M, Rosemffet MG, Otaola M, Cazenave T, Barbich T, et al. Clinical variables and lung ultrasonography for the screening of interstitial lung disease in patients with rheumatoid arthritis. Clin Rheumatol. 2025; 44: 3167-75.

[38] Vermant M, Kalkanis A, Jacob J, Goos T, Cortesi EE, Cypers H, et al. Lung ultrasound outperforms symptom-based screening to detect interstitial lung disease associated with rheumatoid arthritis. RMD Open. 2025; 11: e005283.

[39] Zheng S, Zhou Z, Du G, Chen Q, Chen S, Lin J, et al. The diagnostic utility of lung ultrasound in the assessment of interstitial lung disease associated with rheumatoid arthritis. Arthritis Res Ther. 2025; 27: 159.

[40] Vicente-Rabaneda EF, Möller I, Mata A, Montes N, Rodríguez-Vargas GS, Coronel L, et al. A Proposal for a New Lung Ultrasound Score in Rheumatoid Arthritis: The Reliability of Lung Ultrasound for Rheumatoid Arthritis-Associated Interstitial Lung Disease Diagnosis. J Clin Med. 2025; 14: 3701.

[41] Otaola M, Vasarmidi E, Ottaviani S, Gutierrez M, Dalpiaz MS, Gaser A, et al. Performance of Lung Ultrasound as a Screening Tool for Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Multicenter Study. Chest. 2025; 167: 1687-95.

[42] The Centre for Evidence-Based Medicine. Levels of evidence (March 2009) [Internet]. Centre for Evidence-Based Medicine; c2026 [cited 2026 Jan 24]. Available from: http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/

[43] GRADE [Internet]. The GRADE Working Group; c2004-2025 [cited 2026 Jan 24]. Available from: https://www.gradeworkinggroup.org/

[44] Bandinelli F, Benucci M, Mallia I, Mauro I, Pecani N, Gobbi FL, et al. Do Ultrasound Lung Abnormalities Correlate to Biomarkers and Male Gender in Rheumatoid Arthritis Patients? A Monocentric Cross-Sectional Study. J Clin Med. 2024; 13: 3534.

[45] Demi L, Wolfram F, Klersy C, De Silvestri A, Ferretti VV, Muller M, et al. New International Guidelines and Consensus on the Use of Lung Ultrasound. J Ultrasound Med. 2023; 42: 309-44.

[46] Wang Y, Chen S, Zheng S, Lin J, Hu S, Zhuang J, et al. The role of lung ultrasound B-lines and serum KL-6 in the screening and follow-up of rheumatoid arthritis patients for an identification of interstitial lung disease: review of the literature, proposal for a preliminary algorithm, and clinical application to cases. Arthritis Res Ther. 2021; 23: 212.